Avadel Pharmaceuticals (AVDL) 2024 Wells Fargo Healthcare Conference summary

Launch progress and patient segments

• Over 3,900 patients enrolled in the RyzUp program, with 2,400 initiating therapy and 1,900 remaining on therapy as of June 30, and 500 net patient adds in Q2.

• Patient sources include switch patients, naive patients, and those previously discontinued; switch patients are the largest segment, but uptake among naive and previously discontinued patients is growing.

• The market is dynamic, with significant churn; about 3,000 new starts per year, but 50% discontinue in the first year, and up to 15,000 patients have discontinued oxybate in the last four to five years.

• LUMRYZ is seeing adoption from physicians new to oxybate, indicating market expansion beyond traditional segments.

• The company is focused on building a robust foundation for continued growth, with a larger patient pool than just new starts.

Competitive landscape and market dynamics

• The introduction of authorized generics has mainly impacted the original twice-nightly oxybate, with little effect on LUMRYZ's market position.

• Xywav, a low-sodium competitor, is recognized, but physicians see value in once-nightly LUMRYZ; sodium content is a consideration for some, but LUMRYZ's benefits are broadly acknowledged.

• The market is not mature; significant churn and untapped opportunity exist, with many physicians and patients open to new therapies.

• LUMRYZ's share among naive patients is growing, and the company expects continued expansion as the market evolves.

Legal and regulatory updates

• Recent litigation resulted in denial of an injunction that would have blocked LUMRYZ sales for narcolepsy, allowing the launch to continue.

• An injunction was granted preventing pursuit of approval for idiopathic hypersomnia, which is being appealed.

• Additional legal actions include trade secret misappropriation and antitrust litigation against a competitor, with trials scheduled for Q4 next year.